Straits Times Index
3,308.84 +5.65 (+0.17%) Nikkei
38,612.57 +376.50 (+0.98%) Hang Seng
18,597.63 +19.33 (+0.10%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,880.06 -281.81 (-0.44%) CMC Crypto 200
1,373.14 +60.51 (+4.61%)
BCRX Jan 2025 17.000 put
- Benzinga
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
Monday, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a first-quarter earnings loss of $(0.17) per share versus the consensus estimate loss of $(0.21) per share and $(0.28) reported a year ago. BioCryst Pharma reported sales of $92.8 million, beating the consensus of $85.61 million. The sales increased 34.9% Y/Y, primarily due to $88.9 million in Orladeyo’s net revenue in the first quarter of 2024, up 30% Y/Y. “We are off to a fantastic start to the year with outstanding Orladeyo revenue g
- GuruFocus.com
BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
Significant Growth in ORLADEYO Sales and Strategic Pipeline Advancements Mark the Quarter
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
